Overview

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of ferric citrate tablet in the control of serum phosphorus levels in patients with chronic kidney disease undergoing hemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Sinomune Pharmaceutical Co., Ltd
Treatments:
Sevelamer